Psyence Biomedical Stock Jumps 200% After White House Ibogaine Order News
17 Apr 2026 · 12:18 UTC · CoinCentral RSS Feed · Original source
Read original at CoinCentral RSS Feed →
Summary
Psyence Biomedical (PBM) stock surged 203.8% on April 16, 2026, following news that the White House is preparing an executive order to promote ibogaine research. The company also announced expansion of its Australian clinical trial network from three to five sites for its NPX-5 Phase IIb psilocybin study. Additionally, PBM delayed a previously announced 1-for-6.25 reverse stock split.
Why it matters
The article is fundamentally about a traditional pharmaceutical/biomedical company stock and medical research funding—not cryptocurrency, blockchain, DeFi, or any crypto-adjacent topic. While the article appears on CoinCentral (a crypto news aggregator), the subject matter is entirely outside crypto markets. Bitcoin and altcoins are not influenced by individual biomedical stock movements or pharmaceutical research announcements. There is no causal mechanism, no institutional flow, and no fundamental connection between PBM stock activity and crypto price discovery. The publication on a crypto news site does not make the content crypto-relevant.
Expected impact
This article reports on Psyence Biomedical (PBM), a biomedical company focused on pharmaceutical research, not a cryptocurrency or blockchain-related entity. The news concerns a stock price movement driven by White House policy on ibogaine research and clinical trial expansion. As a non-crypto asset announcement, it has negligible direct impact on Bitcoin or altcoin markets. No mechanism exists for biomedical stock news to materially influence crypto trading, price action, or market sentiment in meaningful timeframes.